NCT01845298View on ClinicalTrials.gov

Immune Activation and Drug Absorption in HIV-Infected Patients

NACompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 14, 2016

Conditions
HIV Infection
Interventions
DRUG

Rifampicin 600 mg

The investigators will administer a single dose of rifampicin 600 mg to study subjects in order to conduct a pharmacokinetic study of rifampicin absorption.

Trial Locations (1)

19102

Drexel University College of Medicine, Philadelphia

All Listed Sponsors
lead

Drexel University

OTHER

NCT01845298 - Immune Activation and Drug Absorption in HIV-Infected Patients | Biotech Hunter | Biotech Hunter